CA2580659C — Corticosteroid having low systemic absorption
Assigned to Bayer Healthcare Animal Health Inc · Expires 2013-02-26 · 13y expired
What this patent protects
The invention provides novel compositions of water-insoluble corticosteroid drug in optional combination with antimicrobial agents and surfactants and either ionic polymers or very low concentrations of non-ionic polymer for topical, otic, and ophthalmic treatment. The invention …
USPTO Abstract
The invention provides novel compositions of water-insoluble corticosteroid drug in optional combination with antimicrobial agents and surfactants and either ionic polymers or very low concentrations of non-ionic polymer for topical, otic, and ophthalmic treatment. The invention provides stable aqueous suspensions where the ingredients remain in such a state so as to allow for immediate re-suspension, when desired, even after extended periods of settling. The invention provides also a method for treating inflammation with low systemic absorption and side effects of the corticosteroid.
Drugs covered by this patent
- Lotemax (LOTEPREDNOL ETABONATE) · Bausch Health
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.